English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
+
Pharmaceuticals
Patient Daily
| Oct 22, 2024
Bristol Myers Squibb funds $2.25M cervical cancer project in Malawi
+
Pharmaceuticals
Patient Daily
| Oct 24, 2024
Navajo Nation passes law increasing taxes on tobacco and nicotine products
+
Pharmaceuticals
Patient Daily
| Oct 22, 2024
American Lung Association welcomes three leaders to Georgia board
+
Pharmaceuticals
Patient Daily
| Oct 24, 2024
Dr. Huda Zoghbi honored by American Academy for her contributions to science
